KERX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KERX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Keryx Biopharmaceuticals's Average Total Inventories for the three months ended in Sep. 2018 was $53.66 Mil. Keryx Biopharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2018 was $8.37 Mil. Hence, Keryx Biopharmaceuticals's Days Inventory for the three months ended in Sep. 2018 was 584.79.
The historical rank and industry rank for Keryx Biopharmaceuticals's Days Inventory or its related term are showing as below:
During the past 13 years, Keryx Biopharmaceuticals's highest Days Inventory was 2886.82. The lowest was 238.78. And the median was 826.68.
Keryx Biopharmaceuticals's Days Inventory increased from Sep. 2017 (300.54) to Sep. 2018 (584.79). It might indicate that Keryx Biopharmaceuticals's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year. Keryx Biopharmaceuticals's Inventory Turnover for the three months ended in Sep. 2018 was 0.16.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Keryx Biopharmaceuticals's Inventory-to-Revenue for the three months ended in Sep. 2018 was 1.91.
The historical data trend for Keryx Biopharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keryx Biopharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Days Inventory | Get a 7-Day Free Trial | - | 5,773.64 | 1,365.48 | 244.72 | 301.67 |
Keryx Biopharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | |
Days Inventory | Get a 7-Day Free Trial | 300.54 | 301.48 | 284.71 | 455.58 | 584.79 |
For the Biotechnology subindustry, Keryx Biopharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Keryx Biopharmaceuticals's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Keryx Biopharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2017 is calculated as
Days Inventory (A: Dec. 2017 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2016 ) | + | Total Inventories (A: Dec. 2017 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2017 ) | * | Days in Period |
= | ( (12.681 | + | 28.695) | / | 2 ) | / | 25.031 | * | 365 |
= | 20.688 | / | 25.031 | * | 365 | ||||
= | 301.67 |
Keryx Biopharmaceuticals's Days Inventory for the quarter that ended in Sep. 2018 is calculated as:
Days Inventory (Q: Sep. 2018 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Jun. 2018 ) | + | Total Inventories (Q: Sep. 2018 )) | / | count ) | / | Cost of Goods Sold (Q: Sep. 2018 ) | * | Days in Period |
= | ( (48.584 | + | 58.736) | / | 2 ) | / | 8.373 | * | 365 / 4 |
= | 53.66 | / | 8.373 | * | 365 / 4 | ||||
= | 584.79 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keryx Biopharmaceuticals (NAS:KERX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Keryx Biopharmaceuticals's Inventory Turnover for the three months ended in Sep. 2018 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 8.373 | / | 53.66 | |
= | 0.16 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Keryx Biopharmaceuticals's Inventory to Revenue for the three months ended in Sep. 2018 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 53.66 | / | 28.036 | |
= | 1.91 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott A Holmes | officer: Chief Financial Officer | C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210 |
Daniel Paul Regan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013 |
Jodie Pope Morrison | director, officer: Interim CEO | C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Mark J Enyedy | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Michael W Rogers | director | C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210 |
Baupost Group Gp, L.l.c. | 10 percent owner | 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116 |
Baupost Group Llc/ma | director, 10 percent owner | 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116 |
Seth A Klarman | 10 percent owner | 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
Greg Madison | director, officer: President and CEO | ONE MARINA PARK DRIVE LEXINGTON MA 02210 |
Brian Adams | officer: General Counsel and Secretary | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
John P. Butler | director | C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
Sak Corp | 10 percent owner | 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
Oliviero James F Iii | officer: Chief Financial Officer | C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 10-02-2018
By Marketwired Marketwired • 08-03-2018
By Robert Gadimian Robert Gadimian • 03-26-2018
By Marketwired Marketwired • 10-01-2018
By Marketwired Marketwired • 05-10-2018
By Marketwired Marketwired • 04-30-2018
By Marketwired Marketwired • 05-25-2018
By GuruFocus GuruFocus • 08-14-2014
By Marketwired Marketwired • 11-29-2018
By Marketwired Marketwired • 04-11-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.